Treatment results of proton beam therapy with chemo-radiotherapy for stage I-III esophageal cancer

Size: px
Start display at page:

Download "Treatment results of proton beam therapy with chemo-radiotherapy for stage I-III esophageal cancer"

Transcription

1 Treatment results of proton beam therapy with chemo-radiotherapy for stage I-III esophageal cancer Nobukazu Fuwa 1, Akinori Takada 2 and Takahiro Kato 3 1;Departments of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Hyogo, Japan 2;Department of Radiation Oncology, Mie University Graduate School of Medicine, Tsu, Mie, Japan 3;Department of Radiation Physics, Southern Tohoku Proton Therapy Center, Koriyama, Fukushima, Japan

2 Background:Although the standard treatment for esophageal cancer is surgery, it is highly invasive and often makes the patient s QOL decreased. Chemo-radiotherapy (CRT) for esophageal cancer has been significantly progressed and this treatment has been acknowledged to be one of the standard treatment. However, the serious late adverse effects such as pulmonary dysfunction and heart damage due to high dose to lung and heart have been raised as a critical issue. Proton beam therapy (PBT) can significantly reduce dose to the normal tissues compared with photon therapy. Therefore, the higher effectiveness and lesser late adverse effects in lung and heart would be expected. Purpose: The aim of our study was to evaluate the outcomes of PBT with CRT in patients with esophageal cancer.

3 Evaluated Items Completion rate of the treatment, Primary effect Patterns of recurrence, Adverse effect Local control rate, Overall survival rate, and Progression survival rate Univariate and multivariate analyses of the prognostic factors on overall survival Comparison with conventional CRT, and previously reported proton therapy

4 Alternating Chemo-Radiation Methods 5-FU:700mg/m 2,d1-5 NDP:130mg/m 2,d6 5-FU:700mg/m 2,d1-5 NDP:130mg/m 2,d6 X ray36gy (1.8Gyx20) Proton 33GyE (2.2GyEx15-18)

5 Patients n= Age: 47~77 yrs (median: 63 yrs) Pathology: Squamous cell ca. 46 (98%), adenoca. 1 (2%) Gender: male 37 (79%) female 10 (21%) PS: 0/1/2 ; 6 (13%) /39 (83%) /2 (4%) Stage (UICC2009):I/II/III ; 10(21%) /12 (26%) /25 (53%) Reasons of chemo radiotherapy: Refusal of surgery 35 (74%) Inoperable 12 (25%) T4 n=8

6 Results n= Completion rate of the treatment: 1 st chemo. 46 (98%), RT 46 (98%) 2 nd chemo. 43 (91%), RT 47 (100%) X ray dose: Gy (median 36Gy) Proton dose: GyE (median 37.4GyE) Primary effect: CR 37 (79%), PR 10 (21%) Patterns of recurrence: local recurrence (within GTV) 11 (23%) distant metastasis 5 (11%) prophylactic area of lymph node 2 (4%)

7 Hematologic Leukopenia Adverse effects( Grade3)CTC ver.4 Neutropenia Anemia Thrombocytopenia 26 (55%) 20 (43%) 2 (4%) 13 (27%) Non-Hematologic Esophagitis 5 (10%) Stenosis, fistula 3 (6%) Pneumonitis 2 (4%) Pericardial effusion 0 (0%) Treatment related death 2 (4%)

8 Local control curve n=47 Local Overall Contol Survival Probability Probability y:68% Time in Year Time in Year

9 Overall survival curve Stage I - III n=47 Stage II - III n=37 Overall Survival Probability y:59% Overall Survival Probability y:55% Time in Year Time in Year

10 Progression free survival curve Stage I - III n=47 Stage II - III n=37 Progression-free Survival Probability y:56% Progression-free Survival Probability y:54% Time in Year Time in Year

11 Results of the Univariate Analysis of the Prognostic Factor on Overall Survival Based on Log rank test Factor Variable Adjusted P value T classification T1, 2 T3, 4 N classification Stage Location Findings of GIF N0 N1-3 I, II III Ut-Mt Lt-AE Clear margin Unclear margin Adjusted HR (95% CI) [referent] (1.117, 22.37) [referent] (0.639, 1.754) [referent] (1.040, ) [referent] (1.040, ) [referent] 3.387(1.184, 9.691) Passage of GIF Yes No SUV max < < [referent] (2.627, ) [referent] (0.730, 8.080)

12 Results of the Multivariate Analysis of the Prognostic Factor on Overall Survival Based on Cox Proportion - Hazard Model Factor Variable Adjusted P value T classification T1, 2 T3, 4 Stage Findings of GIF I, II III Clear margin Unclear margin Adjusted HR (95% CI) [referent] (1.612, ) [referent] (0.253, ) [referent] 0.295(0.068, 1.268) Passage of GIF Yes No SUV max < [referent] (1.035, ) [referent] (0.302, 7.339)

13 Institute N CR rate National Cancer Center(Japan) Comparison with conventional CRT; Stage Ⅱ/Ⅲ(except T4)esophageal ca. Survival rate 3 Years 5 Years Remarks 88 66% 48% 35% Except T4 Tohoku univ % 58% Except T4 Salvage Operation:38% JCOG % 45% 37% Except T4 This study 37 74% 55% T4 (n=8) included

14 Comparison with other proton therapy institutes N Stage chemo X-ray dose Proton dose Survival rate 3 Y OS 3 PFS Remarks Tsukuba univ. 1) 51 T1-4 N Gy n=33 36GyE n=33 79GyE n= % 24.6% Most cases; II-III MD Anderson.2) 62 I-IV GyE 51.7% 40.5% Most cases; II-III, adenoca. Pre-op.; n=29 This study 47 I-III + 36Gy 37.4GyE 59% 56% Most cases; II-III 1) Mizumoto H.et al.strahlen Ther Onkol, ) Lin SH.et al. Int J Radiat oncol Biol Phys, 2012

15 Summary Treatment results of proton beam therapy with chemo-radiotherapy for stage I-III esophageal cancer were favorable. These results are superior to those of conventional CRT, and might be equal to those of surgery. Proton beam therapy combined with CRT can reduce late adverse effects. This method will play an important role for esophageal cancer, and may replace surgery in treating some lesions. In case of operable patient, the optimum dose (e.g Gy ±surgery or over 70Gy) will be an important problem.

Radiation Technology, Hyogo Ion Beam Medical Center, Tatsuno, Hyogo, JAPAN

Radiation Technology, Hyogo Ion Beam Medical Center, Tatsuno, Hyogo, JAPAN Analysis of Visual Loss Due to Radiation- Induced Optic Neuropathy After Particle Therapy for Head and Neck and Skull Base Tumors Adjacent to Optic Nerves Y. Demizu 1, M. Murakami 1, D. Miyawaki 1, Y.

More information

Management of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT

Management of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT Management of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan Kettering Cancer Center Disclosure Consulting

More information

Research and Reviews Journal of Medical and Clinical Oncology

Research and Reviews Journal of Medical and Clinical Oncology Comparison and Prognostic Analysis of Elective Nodal Irradiation Using Definitive Radiotherapy versus Chemoradiotherapy for Treatment of Esophageal Cancer Keita M 1,2, Zhang Xueyuan 1, Deng Wenzhao 1,

More information

Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small cell lung cancer?

Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small cell lung cancer? Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small cell lung cancer? ~A pooled analysis of the literature~ Satomi Yamamoto 1, Kazuyuki

More information

PLACE LABEL HERE. Radiation Therapy Oncology Group Phase II - SBRT - Medically Inoperable I /II NSCLC Follow-up Form. RTOG Study No.

PLACE LABEL HERE. Radiation Therapy Oncology Group Phase II - SBRT - Medically Inoperable I /II NSCLC Follow-up Form. RTOG Study No. Radiation Therapy Oncology Group Phase II - SBRT - Medically Inoperable I /II NSCLC Follow-up Form RTOG Study No. 0813 Case # Name RTOG Patient ID INSTRUCTIONS: Submit this form at the appropriate followup

More information

3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014

3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014 Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R

More information

PTCOG 46. Educational Workshop Session IV. Head & Neck CLINICAL. J. Mizoe (NIRS, Japan)

PTCOG 46. Educational Workshop Session IV. Head & Neck CLINICAL. J. Mizoe (NIRS, Japan) PTCOG 46 Educational Workshop Session IV CLINICAL Head & Neck J. Mizoe (NIRS, Japan) Photon X-Ray γ-ray Fast Neutron Non-Charged Radiation Electron Proton Helium Light Ion Heavy Particle Carbon Neon Argon

More information

Jefferson Digital Commons. Thomas Jefferson University. Maria Werner-Wasik Thomas Jefferson University,

Jefferson Digital Commons. Thomas Jefferson University. Maria Werner-Wasik Thomas Jefferson University, Thomas Jefferson University Jefferson Digital Commons Department of Radiation Oncology Faculty Papers Department of Radiation Oncology May 2008 Increasing tumor volume is predictive of poor overall and

More information

Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05

Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05 Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan

More information

Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva

Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer

More information

Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We

Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David

More information

Dose escalation for NSCLC using conformal RT: 3D and IMRT. Hasan Murshed

Dose escalation for NSCLC using conformal RT: 3D and IMRT. Hasan Murshed Dose escalation for NSCLC using conformal RT: 3D and IMRT. Hasan Murshed Take home message Preliminary data shows CRT technique in NSCLC allows dose escalation to an unprecedented level maintaining cancer

More information

Update on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver

Update on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity

More information

The role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans

The role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans The role of chemoradiotherapy in GE junction and gastric cancer Karin Haustermans Overview Postoperative chemoradiotherapy Preoperative chemoradiotherapy Palliative radiation Technical aspects Overview

More information

Oncotype DX testing in node-positive disease

Oncotype DX testing in node-positive disease Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype

More information

Carbon Ion Radiotherapy for Skull Base and Paracervical Chordomas

Carbon Ion Radiotherapy for Skull Base and Paracervical Chordomas Carbon Ion Radiotherapy for Skull Base and Paracervical Chordomas Azusa Hasegawa, Jun-etsu Mizoe and Hirohiko Tsujii Research Center Hospital for Charged Particle Therapy National Institute of Radiological

More information

Pre- Versus Post-operative Radiotherapy

Pre- Versus Post-operative Radiotherapy Postoperative Radiation and Chemoradiation: Indications and Optimization of Practice Dislosures Clinical trial support from Genentech Inc. Sue S. Yom, MD, PhD Associate Professor UCSF Radiation Oncology

More information

Collection of Recorded Radiotherapy Seminars

Collection of Recorded Radiotherapy Seminars IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology

More information

Radiation Therapy in SCLC. What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department

Radiation Therapy in SCLC. What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department Radiation Therapy in SCLC What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department Background Overview Small Cell Lung cancer constitute about 15 % of all newly

More information

Strategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer

Strategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer Strategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer Daisaku Hirano, MD Department of Urology Higashi- matsuyama Municipal Hospital, Higashi- matsuyama- city, Saitama- prefecture,

More information

San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy

San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy

More information

Hot topics in Radiation Oncology for the Primary Care Providers

Hot topics in Radiation Oncology for the Primary Care Providers Hot topics in Radiation Oncology for the Primary Care Providers Steven Feigenberg, MD Professor Chief, Thoracic Oncology Vice Chair of Clinical Research April 19, 2018 Disclosures NONE 2 Early Stage Disease

More information

Country Presentations of FNCA FY2007 Workshop on Radiation Oncology

Country Presentations of FNCA FY2007 Workshop on Radiation Oncology Country Presentations of FNCA FY2007 Workshop on Radiation Oncology Annex 3 Country presentations on CERVIX-III -China: Total Patients: 18, 8 alive: 1 with metastasis lung, another one metastasis to liver;

More information

Radiation Therapy for Recurrent Esophageal Cancer after Surgery: Clinical Results and Prognostic Factors

Radiation Therapy for Recurrent Esophageal Cancer after Surgery: Clinical Results and Prognostic Factors Radiation Therapy for Recurrent Esophageal Cancer after Surgery: Clinical Results and Prognostic Factors Yoshiyuki Shioyama 1, Katsumasa Nakamura 1, Saiji Ohga 1, Satoshi Nomoto 1, Tomonari Sasaki 1, Toshihiro

More information

ES-SCLC Joint Case Conference. Anthony Paravati Adam Yock

ES-SCLC Joint Case Conference. Anthony Paravati Adam Yock ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar

More information

Newly Diagnosed Cases Cancer Related Death NCI 2006 Data

Newly Diagnosed Cases Cancer Related Death NCI 2006 Data Multi-Disciplinary Management of Esophageal Cancer: Surgical and Medical Steps Forward Alarming Thoracic Twin Towers 200000 150000 UCSF UCD Thoracic Oncology Conference November 21, 2009 100000 50000 0

More information

Management of the patient with Lymph Node Involvement. Michael A Henderson Peter MacCallum Cancer Center Univ of Melbourne

Management of the patient with Lymph Node Involvement. Michael A Henderson Peter MacCallum Cancer Center Univ of Melbourne Management of the patient with Lymph Node Involvement Michael A Henderson Peter MacCallum Cancer Center Univ of Melbourne Lymph Node Field Recurrence Most important prognostic factor for early stage melanoma

More information

Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases

Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation

More information

PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma

PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer

More information

Esophageal and GEJ Adenocarcinoma: Chemo + RT is the Preferred Treatment

Esophageal and GEJ Adenocarcinoma: Chemo + RT is the Preferred Treatment Esophageal and GEJ Adenocarcinoma: Chemo + RT is the Preferred Treatment David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan-Kettering Cancer Center Preop Therapy in Esophageal and

More information

Adjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support

Adjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no

More information

ONCOLOGY LETTERS 10: , 2015

ONCOLOGY LETTERS 10: , 2015 ONCOLOGY LETTERS 10: 201-205, 2015 Proton beam therapy for locally advanced and unresectable (T4bN0M0) squamous cell carcinoma of the ethmoid sinus: A report of seven cases and a literature review TAKASHI

More information

Stereotactic Body Radiation Therapy and Radiofrequency Ablation 2014 Masters of Minimally Invasive Surgery

Stereotactic Body Radiation Therapy and Radiofrequency Ablation 2014 Masters of Minimally Invasive Surgery Stereotactic Body Radiation Therapy and Radiofrequency Ablation 2014 Masters of Minimally Invasive Surgery Matthew Hartwig, M.D. Duke Cancer Institute Case Presentation I: Patient ER 74 y/o male with A1A

More information

Prognostic Impact of Hyperglycemia in Patients with Locally Advanced Squamous Cell Carcinoma of Cervix Receiving Definite Radiotherapy

Prognostic Impact of Hyperglycemia in Patients with Locally Advanced Squamous Cell Carcinoma of Cervix Receiving Definite Radiotherapy Prognostic Impact of Hyperglycemia in Patients with Locally Advanced Squamous Cell Carcinoma of Cervix Receiving Definite Radiotherapy 2016.04.08 KCCH 김문홍 DM and prediabetes in cancer Negative impact on

More information

Optimal Management of Isolated HER2+ve Brain Metastases

Optimal Management of Isolated HER2+ve Brain Metastases Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not

More information

NRG Oncology Lung Cancer Portfolio 2016

NRG Oncology Lung Cancer Portfolio 2016 NRG Oncology Lung Cancer Portfolio 2016 Roy Decker, MD PhD Yale Cancer Center Walter J Curran, Jr, MD Winship Cancer Institute of Emory University NRG Oncology Lung Cancer Selected Discussion Stage III

More information

A retrospective study of californium-252 neutron brachytherapy combined with EBRT versus 3D-CRT in the treatment of esophageal squamous cell cancer

A retrospective study of californium-252 neutron brachytherapy combined with EBRT versus 3D-CRT in the treatment of esophageal squamous cell cancer Wang et al. Radiation Oncology (2015) 10:212 DOI 10.1186/s13014-015-0520-7 RESEARCH Open Access A retrospective study of californium-252 neutron brachytherapy combined with EBRT versus 3D-CRT in the treatment

More information

Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón

Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease

More information

Proton Beam Therapy for Hepatocellular Carcinoma. Li Jiamin, MD Wanjie Proton Therapy Center

Proton Beam Therapy for Hepatocellular Carcinoma. Li Jiamin, MD Wanjie Proton Therapy Center Proton Beam Therapy for Hepatocellular Carcinoma Li Jiamin, MD Wanjie Proton Therapy Center 1 1 Hepatocelluar carcinoma (HCC) is one of the most common cancers worldwide It is the eighth most common neoplasm

More information

Adjuvant Chemotherapy

Adjuvant Chemotherapy State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant

More information

Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer

Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer Kazi S. Manir MD,DNB,ECMO,PDCR Clinical Tutor Department of Radiotherapy R. G. Kar Medical College and Hospital, Kolkata SCLC 15% of lung

More information

Insights into Thymic Epithelial Tumors: Radiation Therapy

Insights into Thymic Epithelial Tumors: Radiation Therapy Insights into Thymic Epithelial Tumors: Radiation Therapy Charles R. Thomas, MD Professor and Chairman, Department of Radiation Medicine Professor, Department of Medicine, Division of Hematology/Medical

More information

We have previously reported good clinical results

We have previously reported good clinical results J Neurosurg 113:48 52, 2010 Gamma Knife surgery as sole treatment for multiple brain metastases: 2-center retrospective review of 1508 cases meeting the inclusion criteria of the JLGK0901 multi-institutional

More information

Outcome of nonsurgical treatment for locally advanced thymic tumors

Outcome of nonsurgical treatment for locally advanced thymic tumors Original Article Outcome of nonsurgical treatment for locally advanced thymic tumors Chang-Lu Wang 1, Lan-Ting Gao 1, Chang-Xing Lv 1, Lei Zhu 2, Wen-Tao Fang 3 1 Department of Radiation Oncology, 2 Department

More information

UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER

UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER Susan Davidson, MD Professor Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Colorado- Denver Anatomy Review

More information

Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy

Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy Mitsui Memorial Hospital Department of Breast and Endocine surgery Daisuke Ota No financial support

More information

Radiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York

Radiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective

More information

Controversies in management of squamous esophageal cancer

Controversies in management of squamous esophageal cancer 2015.06.12 12.47.48 Page 4(1) IS-1 Controversies in management of squamous esophageal cancer C S Pramesh Thoracic Surgery, Department of Surgical Oncology, Tata Memorial Centre, India In Asia, squamous

More information

Clinical Aspects of Proton Therapy in Lung Cancer. Joe Y. Chang, MD, PhD Associate Professor

Clinical Aspects of Proton Therapy in Lung Cancer. Joe Y. Chang, MD, PhD Associate Professor Clinical Aspects of Proton Therapy in Lung Cancer Joe Y. Chang, MD, PhD Associate Professor Clinical Service Chief Thoracic Radiation Oncology Lung Cancer Basic Factors No. 1 cancer killer 161,840 patients

More information

Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes

Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,

More information

The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.

The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:

More information

Neoadjuvant Treatment of. of Radiotherapy

Neoadjuvant Treatment of. of Radiotherapy Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect

More information

11/28/2018. Proton Therapy for Liver Cancer: Who, Why, and How. Disclosures. Michael Chuong, MD. None

11/28/2018. Proton Therapy for Liver Cancer: Who, Why, and How. Disclosures. Michael Chuong, MD. None Proton Therapy for Liver Cancer: Who, Why, and How Michael Chuong, MD Disclosures None 1 Rationale for proton therapy Hepatic toxicity Biliary toxicity GI toxicity Potentially significant benefit especially

More information

Demands and Perspectives of Hadron Therapy

Demands and Perspectives of Hadron Therapy Demands and Perspectives of Hadron Therapy Alexander Lin, M.D. Assistant Professor University of Pennsylvania Direction of Operations Roberts Proton Therapy Center Disclosures Teva Pharmaceuticals: Advisory

More information

Sponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )

Sponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere ) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

Prognostic factors and treatment outcome after radiotherapy in cervical cancer patients with isolated para-aortic lymph node metastases

Prognostic factors and treatment outcome after radiotherapy in cervical cancer patients with isolated para-aortic lymph node metastases Original Article J Gynecol Oncol Vol. 24, No. 3:229-235 pissn 2005-0380 eissn 2005-0399 Prognostic factors and treatment outcome after radiotherapy in cervical cancer patients with isolated para-aortic

More information

Practice changing studies in lung cancer 2017

Practice changing studies in lung cancer 2017 1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received

More information

Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer

Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm

More information

GASTRIC & PANCREATIC CANCER

GASTRIC & PANCREATIC CANCER GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org

More information

Sacral Chordoma: The Loma Linda University Radiation Medicine Experience. Kevin Yiee MD, MPH Resident Physician

Sacral Chordoma: The Loma Linda University Radiation Medicine Experience. Kevin Yiee MD, MPH Resident Physician Sacral Chordoma: The Loma Linda University Radiation Medicine Experience Kevin Yiee MD, MPH Resident Physician What is a chordoma? 1 st chordoma discovered in clivus by Virchow and Luschka 1856 Rare tumor

More information

Erectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer. William M. Mendenhall, MD

Erectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer. William M. Mendenhall, MD Erectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer William M. Mendenhall, MD Meta-Analysis of Probability of Maintaining Erectile Function after Treatment of Localized Cancer Treatment

More information

Combining chemotherapy and radiotherapy of the chest

Combining chemotherapy and radiotherapy of the chest How to combine chemotherapy, targeted agents and radiotherapy in locally advanced NSCLC? Dirk De Ruysscher, MD, PhD Radiation Oncologist Professor of Radiation Oncology Leuven Cancer Institute Department

More information

Clinical results of definitive-dose (50 Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer

Clinical results of definitive-dose (50 Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer DOI 10.1007/s10147-014-0736-9 ORIGINAL ARTICLE Clinical results of definitive-dose (50 Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer Kazuki Ishikawa Kiyoshi Nakamatsu

More information

Clinical Case Conference Melanoma

Clinical Case Conference Melanoma Clinical Case Conference Melanoma Epidemiology ~60,000 cases and 8,000 deaths per year in US Caucasian:African American = 10:1 15% arise from existing nevi 91% are cutaneous 15% are LN+ at presentation

More information

Lung Cancer Epidemiology. AJCC Staging 6 th edition

Lung Cancer Epidemiology. AJCC Staging 6 th edition Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON

More information

Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma

Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma Makita et al. Radiation Oncology 2014, 9:26 RESEARCH Open Access Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma Chiyoko Makita 1*, Tatsuya Nakamura 2, Akinori Takada

More information

Treatment outcomes of patients with small cell lung cancer without prophylactic cranial irradiation

Treatment outcomes of patients with small cell lung cancer without prophylactic cranial irradiation Original Article Treatment outcomes of patients with small cell lung cancer without prophylactic cranial irradiation Masakuni Sakaguchi 1, Toshiya Maebayashi 1, Takuya Aizawa 1, Naoya Ishibashi 1, Tsutomu

More information

OPTIMA Phase III Clinical Trial: Study Design and Protocols

OPTIMA Phase III Clinical Trial: Study Design and Protocols OPTIMA Phase III Clinical Trial: Study Design and Protocols Riccardo Lencioni, MD, FSIR, EBIR Professor of Radiology University of Pisa School of Medicine Division of Diagnostic Imaging & Intervention

More information

Meta analysis in Rectal Cancer

Meta analysis in Rectal Cancer Meta analysis in Rectal Cancer Dr. Monica Irukulla Professor and Head Department of Radiation Oncology Nizam s Institute of Medical Sciences hyderabad Areas of meta analysis in rectal cancers Epidemiology

More information

Prognostic factors in patients with thoracic esophageal carcinoma staged pt 1-4a N 0 M 0 undergone esophagectomy with three-field lymphadenectomy

Prognostic factors in patients with thoracic esophageal carcinoma staged pt 1-4a N 0 M 0 undergone esophagectomy with three-field lymphadenectomy Original Article Page 1 of 7 Prognostic factors in patients with thoracic esophageal carcinoma staged pt 1-4a N 0 M 0 undergone esophagectomy with three-field lymphadenectomy Xiaohui Chen 1, Junqiang Chen

More information

Chapter 5 Stage III and IVa disease

Chapter 5 Stage III and IVa disease Page 55 Chapter 5 Stage III and IVa disease Overview Concurrent chemoradiotherapy (CCRT) is recommended for stage III and IVa disease. Recommended regimen for the chemotherapy portion generally include

More information

Where are we with radiotherapy for biliary tract cancers?

Where are we with radiotherapy for biliary tract cancers? Where are we with radiotherapy for biliary tract cancers? Professor Maria A. Hawkins Associate Professor in Clinical Oncology MRC Group Leader/Honorary Consultant Clinical Oncologist CRUK MRC Oxford Institute

More information

Prophylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer

Prophylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer Prophylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer Dr Neil Bayman Consultant Clinical Oncology ESMO-Christie Preceptorship Programme in Lung Cancer, March

More information

Might Adaptive Radiotherapy in NSCLC be feasible in clinical practice?

Might Adaptive Radiotherapy in NSCLC be feasible in clinical practice? Might Adaptive Radiotherapy in NSCLC be feasible in clinical practice? E.Molfese, P.Matteucci, A.Iurato, L.E.Trodella, A.Sicilia, B.Floreno, S.Ramella, L.Trodella Radioterapia Oncologica, Università Campus

More information

Two Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens

Two Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens 1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days

More information

Head and Neck Reirradiation: Perils and Practice

Head and Neck Reirradiation: Perils and Practice Head and Neck Reirradiation: Perils and Practice David J. Sher, MD, MPH Department of Radiation Oncology Dana-Farber Cancer Institute/ Brigham and Women s Hospital Conflicts of Interest No conflicts of

More information

Original Article. Yuri Jeong, MD 1, Sang-wook Lee, MD, PhD 2. Introduction

Original Article. Yuri Jeong, MD 1, Sang-wook Lee, MD, PhD 2. Introduction Original Article Radiat Oncol J 218;36(4):295-33 https://doi.org/1.3857/roj.218.43 pissn 2234-19 eissn 2234-3156 Tumor volume/metabolic information can improve the prognostication of anatomy based staging

More information

肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部

肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 Outline Current status of radiation oncology in lung cancer Focused on stage III non-small cell lung cancer Radiation

More information

HISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018

HISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018 30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective

More information

Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery

Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery ORIGINAL ARTICLE Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery Ann C. Raldow, BS,* Veronica L. Chiang, MD,w Jonathan P.

More information

Si Hyun Bae, 1,2,3 Do Seon Song, 1,2,3 Myeong Jun Song, 1,4 Woo Jin Chung, 1,5

Si Hyun Bae, 1,2,3 Do Seon Song, 1,2,3 Myeong Jun Song, 1,4 Woo Jin Chung, 1,5 Comparison of efficacy between hepatic arterial infusion chemotherapy and sorafenib in advanced hepatocellular carcinoma with portal vein tumor thrombosis 1,2,3 Si Hyun Bae, 1,2,3 Do Seon Song, 1,2,3 Myeong

More information

DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID

DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;

More information

Update: Chronic Lymphocytic Leukemia

Update: Chronic Lymphocytic Leukemia ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8

More information

Isotopes and Palliative Radiotherapy for bone metastases

Isotopes and Palliative Radiotherapy for bone metastases Isotopes and Palliative Radiotherapy for bone metastases Rationale for Bone-seeking Isotope Therapies in Prostate Cancer > 90% of patients with advanced prostate cancer have bone metastases which can be

More information

Stereotactic radiotherapy

Stereotactic radiotherapy Stereotactic radiotherapy Influence of patient positioning and fixation on treatment planning - clinical results Frank Zimmermann Institut für Radioonkologie Universitätsspital Basel Petersgraben 4 CH

More information

Correlation of intermediate risk factors with prognostic factors in patients with early cervical cancer

Correlation of intermediate risk factors with prognostic factors in patients with early cervical cancer 대한부인종양콜포스코피학회제 24 차학술대회 Correlation of intermediate risk factors with prognostic factors in patients with early cervical cancer Seoul National University Bundang Hospital Eun Jung Soh, M.D. Cervical cancer

More information

Non-small cell lung cancer (NSCLC) is a common cause

Non-small cell lung cancer (NSCLC) is a common cause ORIGINAL ARTICLE Results of Proton Beam Therapy without Concurrent Chemotherapy for Patients with Unresectable Stage III Non-small Cell Lung Cancer Yoshiko Oshiro, MD,* Masashi Mizumoto, MD,* Toshiyuki

More information

Overview of Radiotherapy for Clinically Localized Prostate Cancer

Overview of Radiotherapy for Clinically Localized Prostate Cancer Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive

More information

Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents

Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center

More information

When to Integrate Surgery for Metatstatic Urothelial Cancers

When to Integrate Surgery for Metatstatic Urothelial Cancers When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male

More information

Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma

Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating

More information

Introduction ORIGINAL RESEARCH

Introduction ORIGINAL RESEARCH Cancer Medicine ORIGINAL RESEARCH Open Access The effect of radiation therapy in the treatment of adult soft tissue sarcomas of the extremities: a long- term community- based cancer center experience Jeffrey

More information

Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology

Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant

More information

News Briefing: Treatment Considerations for Focused Populations

News Briefing: Treatment Considerations for Focused Populations News Briefing: Treatment Considerations for Focused Populations Moderator: Pranshu Mohindra, MD, University of Maryland, Baltimore Reirradiation of Thoracic Cancers with Intensity Modulated Proton Therapy

More information

Management of high risk early cervical cancer - a view of surgeon Dan DY Kim, M.D., Ph.D.

Management of high risk early cervical cancer - a view of surgeon Dan DY Kim, M.D., Ph.D. Management of high risk early cervical cancer - a view of surgeon Dan DY Kim, M.D., Ph.D. Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea

More information

Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study

Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study T Sridhar 1, A Gore 1, I Boiangiu 1, D Machin 2, R P Symonds 3 1. Department of Oncology, Leicester

More information

Surgery versus stereotactic body radiation therapy in medically operable NSCLC

Surgery versus stereotactic body radiation therapy in medically operable NSCLC Surgery versus stereotactic body radiation therapy in medically operable NSCLC David H Harpole Jr, MD Professor of Surgery Associate Professor in Pathology Vice Chief, Division of Surgical Services Duke

More information

All India Institute of Medical Sciences, New Delhi, INDIA. Department of Pediatric Surgery, Medical Oncology, and Radiology

All India Institute of Medical Sciences, New Delhi, INDIA. Department of Pediatric Surgery, Medical Oncology, and Radiology All India Institute of Medical Sciences, New Delhi, INDIA Department of Pediatric Surgery, Medical Oncology, and Radiology Clear cell sarcoma of the kidney- rare renal neoplasm second most common renal

More information

HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium

HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium DISCLOSURE OF INTEREST Nothing to declare HEAD AND NECK CANCER -HPV

More information

Adjuvant Chemotherapy for Rectal Cancer: Are we making progress?

Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones

More information